SEC Form 4 · accession 0001140361-16-078260
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — EVP, Chief Medical Officer
Period of report
Aug 26, 2016
Accepted (ET)
Aug 30, 2016 · 9:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 26, 2016 | M | 15,000 | $26.49 | A | 128,878 | D | |
| Common StockF1,F2 | Aug 26, 2016 | S | 15,000 | $95.0616 | D | 113,878 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock (Right to buy Common Stock)F1,F3 | $26.49 | Aug 26, 2016 | M | 15,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 15,000 | 50,225 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 12, 2016.
- F2The price in column 4 is the weighted average. The price actually received ranged from $94.47 to $95.61. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.